27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Monday, Stifel Nicolaus analyst Brian Klein initiated coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Buy rating and $24.00 price target.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
In the report, Stifel Nicolaus noted, “We view ETC-1002 as an impressive cholesterol lowering agent that directly targets several unmet needs in a well-established disease space and addresses a multibillion dollar commercial opportunity. ETC-1002 is a novel, oral small molecule in clinical studies for the treatment of LDL-cholesterol (LDL-C) in patients with high cholesterol (hypercholesterolemia) who cannot tolerate standard therapy with statins. Recent results from Esperion's Phase 2a studies demonstrate consistent lowering of LDL-C levels of 27%-40% in the target population as a single agent, which we note is superior to currently available alternatives to statins; the safety and side-effect profile was consistent with placebo. With an addressable population of over two million patients in the U.S. alone, we believe the statin-intolerant market represents a compelling commercial opportunity of over $2 billion; given the success of statins in lowering cholesterol and improving cardiovascular outcomes, we believe that the clinical and regulatory pathways for drugs targeting LDL-C are well established and help de-risk Esperion's current development strategy.”
Esperion Therapeutics closed on Friday at $16.90.